Urological oncology is at the core of the clinical and scientific activity of the team led by Professor Pierluigi Bove, with experience built on hundreds of oncological procedures, robotic and ablative surgeries, and medical treatments.

It refers to the integrated approach to prevention, diagnosis, and treatment of tumors affecting the urinary and reproductive systems, including:

• Prostate cancer (early diagnosis, staging, curative therapy – robotic radical prostatectomy – and follow-up)
• Kidney cancer (robotic partial nephrectomy / tumor enucleation – radical nephrectomy)
• Bladder cancer (robotic cystectomy, bladder-sparing approaches)
• Upper urinary tract cancers (urothelial carcinoma)
• Male urogenital cancers (penile and testicular cancer), treated with both oncological and functional approaches

Each patient is guided through a personalized care path based on:

1. Accurate diagnosis using PSA testing, multiparametric MRI, fusion-guided biopsy, advanced staging, and genetic testing (BRCA – Prostatype)

2. Shared decision-making with an oncology team (urologists, oncologists, radiologists, and other specialists)

3. Tailored treatments: robotic surgery, ablative techniques, radiotherapy, medical therapy

4. Structured follow-up to ensure oncological effectiveness while preserving quality of life

Professor Pierluigi Bove is a university lecturer and speaker at numerous scientific congresses. He participates in several national and international clinical trials on urological oncology and has authored dozens of scientific publications on the subject. He has collaborated for years with prestigious European and American centers to develop and refine minimally invasive techniques. He was among the first in Italy to introduce minimally invasive and laparoscopic approaches even for complex or high-risk conditions.

Some symptoms may be silent in early stages, but it’s important not to ignore signals like: blood in the urine (hematuria), difficulty urinating, persistent lower back pain, unexplained weight loss, or changes in urinary flow. A rise in PSA (a simple blood test) may also indicate the need for further evaluation. If any of these symptoms are present, it is essential to consult a specialist for a urological assessment.

No, not always. Today, urological oncology includes a wide range of therapeutic options such as active surveillance, focal therapies, radiotherapy, and systemic treatments. Surgery—whether robotic or minimally invasive—is recommended only when it represents the most effective option for the individual patient, based on tumor type, stage, and overall health condition.

Professor Bove works within a highly specialized setting where each cancer case is evaluated by a multidisciplinary team including urologists, oncologists, radiotherapists, radiologists, and other specialists. This approach ensures the most appropriate and personalized therapy, minimizing risks and enhancing treatment effectiveness—even in the most complex cases.

Professor Pierluigi Bove performs robotic surgery at top-tier facilities such as Policlinico Tor Vergata in Rome, within the Robotic Urology Unit (UOSD URMI), and at the UPMC Salvator Mundi International Hospital in Rome—both equipped with cutting-edge robotic technology. Thanks to his extensive experience and the support of a multidisciplinary team, each patient is followed through all stages: from diagnosis to surgery and post-operative follow-up. To book a consultation or request an evaluation, you can use the dedicated contact form on the website.